Business Context and Reporting Period
This Form 8-K Current Report was filed by DarioHealth Corp. on April 2, 2018, covering events occurring on April 1, 2018. The company is an emerging growth company incorporated in Delaware with principal executive offices in Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and board appointments rather than financial performance.
Material Changes
- Board Appointment: On April 1, 2018, Ori Zanco was appointed to the Board of Directors to fill an existing vacancy.
- Investor Rights: Mr. Zanco was nominated by Agate JT Healthcare Fund L.P., the lead investor in private placement offerings closed between February 28, 2018, and March 6, 2018. The appointment fulfills a contractual right granted to Agate to appoint a director while maintaining ownership of over 5% of outstanding common stock.
- Executive Compensation Vote: Following the December 4, 2017 Annual Meeting, the Board confirmed that advisory votes on named executive officer compensation will be held every three years, aligning with stockholder recommendations.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks and contingencies. It notes that there are no undisclosed arrangements or transactions involving Mr. Zanco requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the closing dates and terms of the private placement offerings with Agate JT Healthcare Fund L.P. referenced in the filing.
- Confirm Ori Zanco's current ownership percentage in the company to ensure the 5% threshold for board representation is maintained.
- Review the company's most recent 10-K or 10-Q for financial metrics, as this 8-K does not contain financial data.